Good nutrition is vital for building up mental resilience in trying times. These are the mood-boosting vitamins and minerals to have in your mental first aid kit, says nutritionist Rob Hobson

Our minds have a lot to deal with; be it overscheduled lives, the need to succeed running us into the ground both, or the rise of burnout in the workplace. That's even before we get into the uncertainty of the current Covid-19 health crisis. According to research by the Health Survey for England approximately one in four of us in the UK will experience a mental health problem in any given year and experts are predicting numbers will rise in response to lockdown and the effects of Covid-19 on the workforce and the economy.

In Mental Health Awareness Week this week, Archbishop Justin Welby, who has talked openly about his own mental health issues, summed up the national mood when he told the BBC that there was "an overwhelming sense the world is getting more and more difficult and gloomy".

There's a lot we can do to look after our mental health and nutrition is one of the frontline ways we can support ourselves, to help build-up not just physical immunity but what psychologist Dr Meg Arrol calls 'psychological immunity'.

A strong mind is just the same as a strong immune system in that it means being able to cope well with lifes demands and with the current landscape shifting so greatly and quickly its beneficial to build up what I call psychological immunity," says Dr Arroll, a chartered psychologist working with supplement brand Healthspan.

"There are many strategies we can use to help build psychological immunity," she says, "including only checking reputable sourcing of information and talking about our feelings and taking good care of our physical health. Taking supplements that have been shown to support the mind is also a good way to help boost psychological immunity as chronic stress and traumatic experiences can deplete important vitamins and minerals."

The links between diet and mood are well documented and there are many key nutrients that play a role in maintaining energy levels and reducing the risk of depression, but it's not always easy to eat well. Low mood and poor mental health can take their toll on the food choices you make, and this can leave gaps in the diet. This is where the sensible use of supplements can be really helpful

B vitamins support the nervous system and are a key 'strong mind' ally. They can help you feel less tired, help memory and altogether make you feel like you have more clarity. They are essential for energy production in cells, including brain cells, where they help make neurotransmitters (the brains communication chemicals). They also help with nerve conduction - meaning that they help make sure messages are passed on.

When you're stressed and anxious, your B vitamins can become rapidly depleted, which can even make your stress symptoms worse. Lack of B vitamins can lead to anxiety and irritability. All the more reason to keep your levels healthy.

What the research says: Women with low levels of vitamin B1 (thiamin) are less likely to feel composed and confident and more likely to be depressed than those with higher levels, according to researchers. When they increased their intake of vitamin B1, however, they reported a marked improvement in mood and self-confidence as their thiamin levels increased. Other studies show that correcting low levels of vitamin B2 (riboflavin), vitamin B6 (pyridoxine) and vitamin B12 has beneficial effects on well-being, self-confidence and mood.

Try: Healthspan High Strength Vitamin B Complex, 8.95 for 120 tablets, Solgar Megasorb B Complex high potency, 13.99 for 50

A good nights sleep goes a long way to promoting good mental health and mood during the day. Magnesium is involved in the production of melatonin, the hormone that controls our sleep cycle. It's a mineral that's essential for energy metabolism, reducing tiredness and fatigue and is also vital for the normal functioning of the nervous system and psychological health.

Like B vitamins, magnesium is more rapidly depleted during times of stress and anxiety creating a vicious cycle - low levels of magnesium also exacerbate these feelings. During times of stress and anxiety, a magnesium supplement may be useful to balance mood and mental wellbeing.

If you suffer from PMS, magnesium is your friend. Magnesium levels appear to be significantly lower. Taking magnesium supplements every day for two months significantly improved symptoms associated with pain and bloating, one study found. Other research has shown how supplementing with magnesium may also help to relieve premenstrual mood changes.

MORE GLOSS: Why you need magnesium in midlife more than ever

Try: Healthspan Opti-Magnesium, 10.95 for 90 tablets or Magnesium Flakes Bath Soak, 9.95, 1kg pouch. NeuroMag for brain health by Life Extension 32 for 50.

You probably know that probiotics are live bacteria that have beneficial effects on digestive health and general immunity. More recent research suggests they may also influence our psychological health, the gut-brain axis.

Although research is in its early stages, probiotic bacteria are now believed to have indirect effects on our brain by regulating the production of serotonin within the gut wall. Serotonin helps to lift mood and improve anxiety and depression. As much as 95 per cent of our serotonin is made within the lining of our digestive tract.

Try: Symprove Liquid probiotic, from 21.95

MORE GLOSS: Which probiotics to eat, drink and buy - and why

5-Hydroxytryptophan, or 5-HTP, is an amino acid that is found naturally in the body and which can be converted into serotonin that regulates mood as well as melatonin, which helps to regulate the sleep cycle.

5-HTP appears to improve the structure of your sleep by extending the amount of time you spend in REM sleep in which your brain processes memories. Getting sufficient REM sleep is essential for feeling rejuvenated during the day which will inevitably impact on your mental state and ability to perform your daily tasks.

Several studies show that 5-HTP supplements have a positive effect on low mood and are better than placebo in treating depression, with benefits usually occurring within two weeks

One study, involving 60 people with a first episode of depression, showed that is was almost as good as prescription antidepressants. It compared the effects of 5-HTP with the prescribed antidepressant drug, fluoxetine, for eight weeks. Both groups showed a significant and nearly equal improvement in depression, starting from the second week of treatment and increasing over the eight weeks. By the end of the study, 73 per cent of those taking 5-HTP and 80 per cent taking fluoxetine felt significantly better.

Try: 5-HTP, 13.95 for 60 tablets or Serotone 5-HTP by Higher Nature 32.70 for 90 capsules

I've tackled these together because omega-3 fish oils and vitamin D work hand in hand to optimise serotonin (good mood hormone) levels in the brain. You don't need to know the science but if you're interested...

Serotonin needs an amino acid, called tryptophan (see 5HTP above) to convert it to a usable form in the brain. That conversion is activated by vitamin D.

Once serotonin is made, EPA (one of the long-chain omega-3 fatty acids found in fish oils) helps brain cells release it into their communication gaps (synapses) to stimulate surrounding brain cells. Once serotonin arrives at a new brain cell, the presence of another long-chain omega-3 fish oil, DHA, helps the serotonin message to be received by increasing the fluidity of the cell membrane fluidity. Good levels of vitamin D and both omega-3s are therefore needed for optimum brain function.

Researchers have suggested that lack of vitamin D, EPA or DHA contributes to a number of psychiatric disorders and depression. Clinical trials suggest that omega-3 fish oils can improve depression, prolong periods of remission from depressive episodes and improve the short-term course of the illness in those affected.

How much omega 3 do you need to take to get a beneficial anti-depressive effect? Look for 650mg total DHA and EPA per day. Adding fish oils (2g per day) to usual drug treatment for depression has also been shown to significantly improve symptoms within two weeks, compared with placebo.

Try: Healthspan High Strength Omega 3, 11.95 for 360 capsules, Bare Biology Lion Heart Pure Omega 3, 28.50 and Healthspan Super Strength Vitamin D3, 8.95 for 120 capsules, D-Lux 3000 Vitamin D Spray 7.99

MORE GLOSS: The best vitamin D supplements to support your immune system right now

NB: Supplements do have a role to play in maintaining overall health and especially people who do not manage to eat a well-balanced diet. Exploring the use of supplements to complement your mood and overall health regime may be a good option but do check if you are on any SSRIs (Selective Serotonin Reuptake Inhibitor, SSRI are antidepressants) or medication and look for supplements that are made to GMP (good manufacturing practice) such as those made by Healthspan which means they are made to high pharmaceutical standards so simply put, what it says is on the packet is actually in the product you are taking. Rob Hobson is a Registered Nutritionist and Head of Nutrition for Healthspan.

More:
The best supplements to look after your mind and mental health - Get The Gloss

Recommendation and review posted by Bethany Smith

The Global Packaging Coatings Market Analysis to 2027 is a specialized and in-depth study of the chemicals and materials industry with a special focus on the global market trend analysis. The report aims to provide an overview of packaging coatings market with detailed market segmentation by type, substrate, application, end user and geography. The global packaging coatings market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading packaging coatings market players and offers key trends and opportunities in the market.

Download PDF Sample Copy Here https://www.theinsightpartners.com/sample/TIPRE00004238/

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Chemicals and Materials, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Packaging Coatings market globally. This report on Packaging Coatings market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Major vendors covered in this report:

Get Discount on This Report at https://www.theinsightpartners.com/discount/TIPRE00004238/

Packaging coatings are coatings having good adhesion to metal and plastic substrates along with high chemical resistance. Such coatings effectively serve protection, performance as well as decoration purposes for metal cans, plastic tubes, or any other substrate used in packaging. Coating technology in the food packaging sector allows more rational use of the materials used within this sector. Replacement of multi-layer, heavy structures with multi-functional thin layer will not only help to reduce the upstream amount of packaging material but also improve the functionality of the final packaging, thereby, ensuring shelf life extension. The packaging coatings market is coming up with highly sophisticated and engineered coatings to meet consumer convenience.

The packaging coatings market is anticipated to grow in the forecast period owing to driving factors such as rapid growth of the e-commerce industry and high demands of flexible packaging for consumer goods. Moreover, the growing demands for canned food and beverages coupled with aerosol cans for personal and healthcare industry further fuel the packaging coatings market growth. However, rising concerns on amount of Bisphenol-A in packaging coatings may limit market growth. The growth opportunity for key players in the packaging coatings market lies in the production of environment-friendly packaging coatings.

Purchase this Report at https://www.theinsightpartners.com/buy/TIPRE00004238/

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Packaging Coatings market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also predicts the influence of different industry aspects on the Packaging Coatings market segments and regions.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global packaging coatings market based on various segments. It also provides market size and forecast estimates from the year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The packaging coatings market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

See the original post here:
Packaging Coatings Market by Top Key Players, Applications and Forecast Report 2020-2027 - Cole of Duty

Recommendation and review posted by Bethany Smith

Four of six patients in case series were weaned off respiratory support

An investigational allogeneic cell therapy using cardiosphere-derived cells (CDC) showed an acceptable safety profile with early evidence of efficacy in the treatment of very severe Covid-19 in a case series involving six patients treated at Cedars-Sinai Medical Center in Los Angeles.

All six patients treated with the intravenous allogeneic CDC formulation CAP-1002 (Capricor Therapeutics) as a compassionate therapy required respiratory support prior to treatment, with five on mechanical ventilation.

No adverse events related to the treatment were reported, and four of the six patients were successfully weaned from respiratory support and were discharged from the hospital as of late April.

The other two patients are still alive, but remain intubated, Cedars-Sinai cardiologist Raj Makkar, MD, confirmed to BreakingMED Wednesday, May 13.

While we are encouraged by these findings, it is important to point out that the only way that we can assess the efficacy of this treatment in a definitive way is with a randomized clinical trial, and that is what we intend to do, Makkar said.

He added that the clinical trial, which is in the planning stages, is likely to include Covid-19 patients who are not as critically ill as the six in the case series.

All of these patients required respiratory support and they were all on a downward trajectory when treated, he said. They were getting worse and we had nothing else to offer them.

Cardiosphere-derived cells are stromal/progenitor cells from heart tissue with a distinctive antigenic profile (CD105+, CD45-, CD90low).

In their case series, published in the journal Basic Research in Cardiology, Makkar and colleagues noted that the cells are entirely distinct from the controversial c-kit+ putative cardiac progenitors, which have been the subject of various retracted studies.

Since CDCs were first isolated in 2007, the cells have been tested in more than 200 patients in clinical trials for a variety of conditions with a good safety profile, including in young boys with Duchenne muscular dystrophy.

Makkar said the anti-inflammatory and antifibrotic properties of CDCs in animal models make them a possible target therapy for Covid-19.

The prior testing gave us reasonable confidence that this treatment was safe, he said, adding that there is also evidence of a favorable effect on the same type of proinflammatory cytokines that are up-regulated in Covid-19.

Comparisons to mesenchymal stem cells (MSCs) in pre-clinical models suggest that CDCs may also be more effective for paracrine factor secretion and myocardial remodeling.

Given the safety record of CDCs in humans, and the substantial body of evidence confirming relevant disease-modifying bioactivity, applicability to Covid-19 seemed compelling, particularly in the hyperinflammatory stage of the illness, the researchers wrote.

All six patients treated with the intravenous CDC formulation had severe, confirmed Covid-19 with respiratory failure and they were not receiving any other experimental agent, with the exception of hydroxychloroquine and tocilizumab.

Lack of clinical improvement or deterioration despite standard care was the primary reason for considering patients for treatment with CAP-1002. Exclusion criteria included known hypersensitivity to DMSO, which is a component of CAP-1002; prior stem cell therapy; pre-existing terminal illness; and need for mechanical circulatory support and dialysis.

In general, patients with multi-organ failure who were deemed to be too sick for any intervention were excluded from the study, Makkar and colleagues wrote.

All patients had acute respiratory distress syndrome (ARDS) prior to infusion, with decreased PaO2/FiO2 ratios (range 69-198; median 142), diffuse bilateral pulmonary infiltrates on chest imaging and evidence of preserved cardiac function on transthoracic echocardiography (LVEF range, 50-75%). SOFA scores ranged from 2 to 8 prior to stem cell treatment.

The six patients (age range, 19-75 years) had IV infusions of CAP-1002 containing 150 million allogeneic CDCs, and two of the six had a second dose of the treatment.

Following treatment, four patients (67%) were weaned from respiratory support and discharged from the hospital.

A contemporaneous control group of critically ill Covid-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization, the researchers wrote.

Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in five of the six patients (range of all patients 252.891029.90 ng/ml).

Absolute lymphocyte counts were low in five of the six patients at baseline (range 0.260.82 103/l) but had increased in 3 of these five at last follow-up (range 0.231.02 103/l).

Administration of CAP-1002 as a compassionate therapy for patients with severe Covid-19 and significant comorbidities was safe, well tolerated without serious adverse events, and associated with clinical improvement, as evidenced by extubation (or prevention of intubation, the researchers wrote.

Stem cell therapy utilizing cardiosphere-derived cells (CDC) showed an acceptable safety profile with early evidence of efficacy in the treatment of very severe Covid-19 in an early case series involving 6 patients treated at Cedars-Sinai Medical Center, Los Angeles.

No adverse events related to the treatment were reported, and four of the six patients were successfully weaned from respiratory support and were discharged from the hospital.

Salynn Boyles, Contributing Writer, BreakingMED

Funding for this story was provided by the Smidt Family Foundation. The cell product, CAP-1002, was provided by manufacturer Capricor Therapeutics.

ResearcherEduardo Marban reported owning founders equity in Cariricor Therapeutics, and researcher Linda Marban reported being an employee and owning equity in the company.

Cat ID: 125

Topic ID: 79,125,254,930,287,728,932,570,574,730,933,125,190,926,192,927,151,928,925,934

Read the original:
Cardio Stem Cell Therapy Used to Treat Critically Ill Covid-19 Patients - Physician's Weekly

Recommendation and review posted by Bethany Smith

Not intended for UK-based media

- Results from two studies of BAVENCIOto be featured in ASCO press briefing

- Primary efficacy, biomarker and HRQoL analyses for tepotinib, the first MET inhibitor to have received a regulatory approval for NSCLC with METgene alterations

- Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfatargeting TGF-/PD-L1, in second-line NSCLC

ROCKLAND,Massachusetts, May 13, 2020 /PRNewswire/ --EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada,today announced data for its innovative investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program, to be held virtually from May 29-31.

This year, ASCO will be highlightingduring its embargoed presscast on Tuesday, May 26 and at the plenary session on Sunday, May 31the Phase III JAVELIN Bladder 100 study (Abstract# LBA1) of BAVENCIO (avelumab) in the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC)*. Additional data will be presented for early- to late-stage molecules discovered and developed in-house that demonstrate the Company's commitment and relentless drive to discover, develop and deliver innovative treatment options in its hope to turn cancer patients into cancer survivors. Research from several investigator-sponsored and collaborative research studies also will be shared. This includes a late-breaking oral presentation of results of the investigator-sponsored, multicenter Phase II TROPHIMMUN study of avelumab for the treatment of chemotherapy-resistant gestational trophoblastic tumors (Cohort A), which also will be featured in the ASCO press program (Abstract# LBA6008).

"Despite the many advances in cancer treatment, we have an urgency to continue to discover and develop innovative treatment options that will have a major impact on the lives of people living with cancer,"said Luciano Rossetti, Global Head of Research & Development for EMD Serono. "Taking on this challenge, we've applied our deep knowledge of cancer biology to highly focused areas to develop the first-in-class oral MET inhibitor, tepotinib, which received the first approval anywhere in the world for the treatment of NSCLC with MET gene alterations, and our first-in-class bifunctional fusion protein immunotherapy, bintrafusp alfa, both of which have promising outcomes featured at this year's ASCO meeting."

For tepotinib, approved in Japan for the treatment of patients withunresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with METexon 14 (METex14)skipping alterationsand the first oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene alterations to receive a regulatory approval, data will be presented from the primary analysis of the VISION study with promising activity in patients with advanced EGFR/ALK wild-type, METex14 skipping NSCLC who were prospectively enrolled using liquid biopsy or tissue biopsy. Results (Abstract #9556) include6-month follow-updata for the primary endpoint of objective response rate (ORR) as determined by independent review committee. Secondary endpoints include ORR as assessed by investigators, duration of response, disease control rate, progression-free survival, molecular responses, and safety data. Additionally, patient-reported outcomes (PROs) of health-related quality of life (HRQoL) for the VISION study will be presented at the meeting (Abstract# 9575). These outcomes are the first time HRQoL have been reported for patients with METex14skipping NSCLC.

For bintrafusp alfa, a novel bifunctional fusion protein targeting TGF- and PD-L1, two-year follow-up data from a global Phase I study in second-line NSCLC will be presented (Abstract# 9558). These data continue to show manageable safety with durable responses and encouraging long-term survival, especially in patients with high PD-L1 expression (80%). The overall safety profile has remained consistent since the interim analysis, with no new safety signals or deaths and one additional treatment-related discontinuation (blood alkaline phosphatase increased). Studies in the bintrafusp alfa lung cancer program include:

The Company's broad portfolio of investigational DNA damage response (DDR) inhibitors represents multiple development paths, including combinations with other agents and modalities. A trial-in-progress poster (Abstract #TPS4117) will review a multicenter Phase Ib/II study evaluating the safety, tolerability, pharmacokinetics and efficacy of the DNA-PK inhibitor peposertib (formerly M3814) in combination with capecitabine and radiotherapy as neoadjuvant treatment in patients with locally advanced rectal cancer.

*BAVENCIO is under clinical investigation for the first-line maintenance treatment of advanced UC. There is no guarantee that BAVENCIO will be approved for first-line maintenance treatment of advanced UC by any health authority worldwide.

Tepotinib is currently under clinical investigation in NSCLC and not yet approved in any markets outside of Japan.

Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

About BAVENCIO (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.10-12 In November 2014, Merck KGaA, Darmstadt, Germany and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

BAVENCIO Approved Indications

BAVENCIO (avelumab) in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Avelumab is currently approved for patients with MCC in 50 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

BAVENCIO Important Safety Information from the US FDA-Approved Label

BAVENCIO can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis, and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% of patients, including one (0.1%) patient with Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.

BAVENCIO can cause hepatotoxicity and immune-mediated hepatitis, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis occurred with BAVENCIO as a single agent in 0.9% of patients, including two (0.1%) patients with Grade 5, and 11 (0.6%) with Grade 3.

BAVENCIO in combination with axitinib can cause hepatotoxicity with higher than expected frequencies of Grade 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation. Consider more frequent monitoring of liver enzymes as compared to when the drugs are used as monotherapy. Withhold BAVENCIO and axitinib for moderate (Grade 2) hepatotoxicity and permanently discontinue the combination for severe or life-threatening (Grade 3 or 4) hepatotoxicity. Administer corticosteroids as needed. In patients treated with BAVENCIO in combination with axitinib, Grades 3 and 4 increased ALT and AST occurred in 9% and 7% of patients, respectively, and immune-mediated hepatitis occurred in 7% of patients, including 4.9% with Grade 3 or 4.

BAVENCIO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis until resolution. Permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon reinitiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% of patients, including seven (0.4%) with Grade 3.

BAVENCIO can cause immune-mediated endocrinopathies, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.

Monitor patients for signs and symptoms of adrenal insufficiency during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% of patients, including one (0.1%) with Grade 3.

Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) thyroid disorders. Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroiditis, were reported in 6% of patients, including three (0.2%) with Grade 3.

Type 1 diabetes mellitus including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer antihyperglycemics or insulin in patients with severe or life-threatening (Grade 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% of patients, including two cases of Grade 3 hyperglycemia.

BAVENCIO can cause immune-mediated nephritis and renal dysfunction. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% of patients.

BAVENCIO can result in other severe and fatal immune-mediated adverse reactions involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy, if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO as a single agent or in 489 patients who received BAVENCIO in combination with axitinib: myocarditis including fatal cases, pancreatitis including fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barr syndrome, and systemic inflammatory response.

BAVENCIO can cause severe or life-threatening infusion-related reactions. Premedicate patients with an antihistamine and acetaminophen prior to the first 4 infusions and for subsequent infusions based upon clinical judgment and presence/severity of prior infusion reactions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.

BAVENCIO in combination with axitinib can cause major adverse cardiovascular events (MACE) including severe and fatal events. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue BAVENCIO and axitinib for Grade 3-4 cardiovascular events. MACEoccurred in 7% of patients with advanced RCC treated with BAVENCIO in combination with axitinib compared to 3.4% treated with sunitinib. These events included death due to cardiac events (1.4%), Grade 3-4 myocardial infarction (2.8%), and Grade 3-4 congestive heart failure (1.8%).

BAVENCIO can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman not to breastfeed during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.

The most common adverse reactions (all grades, 20%) in patients with metastatic Merkel cell carcinoma (MCC) were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).

Selected treatment-emergent laboratory abnormalities (all grades, 20%) in patients with metastatic MCC were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).

The most common adverse reactions (all grades, 20%) in patients with locally advanced or metastatic urothelial carcinoma (UC) were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%), and urinary tract infection (21%).

Selected laboratory abnormalities (Grades 3-4, 3%) in patients with locally advanced or metastatic UC were hyponatremia (16%), increased gamma-glutamyltransferase (12%), lymphopenia (11%), hyperglycemia (9%), increased alkaline phosphatase (7%), anemia (6%), increased lipase (6%), hyperkalemia (3%), and increased aspartate aminotransferase (3%).

Fatal adverse reactions occurred in 1.8% of patients with advanced renal cell carcinoma (RCC) receiving BAVENCIO in combination with axitinib. These included sudden cardiac death (1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing pancreatitis (0.2%).

The most common adverse reactions (all grades, 20%) in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were diarrhea (62% vs 48%), fatigue (53% vs 54%), hypertension (50% vs 36%), musculoskeletal pain (40% vs 33%), nausea (34% vs 39%), mucositis (34% vs 35%), palmar-plantar erythrodysesthesia (33% vs 34%), dysphonia (31% vs 3.2%), decreased appetite (26% vs 29%), hypothyroidism (25% vs 14%), rash (25% vs 16%), hepatotoxicity (24% vs 18%), cough (23% vs 19%), dyspnea (23% vs 16%), abdominal pain (22% vs 19%), and headache (21% vs 16%).

Selected laboratory abnormalities (all grades, 20%) worsening from baseline in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were blood triglycerides increased (71% vs 48%), blood creatinine increased (62% vs 68%), blood cholesterol increased (57% vs 22%), alanine aminotransferase increased (ALT) (50% vs 46%), aspartate aminotransferase increased (AST) (47% vs 57%), blood sodium decreased (38% vs 37%), lipase increased (37% vs 25%), blood potassium increased (35% vs 28%), platelet count decreased (27% vs 80%), blood bilirubin increased (21% vs 23%), and hemoglobin decreased (21% vs 65%).

Please see full US Prescribing Information and Medication Guide available at http://www.BAVENCIO.com.

About tepotinib

Tepotinib is an oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, including both METex14 skipping alterations and MET amplifications, or MET protein overexpression. Discovered in-house at Merck KGaA, Darmstadt, Germany, it has been designed to have a highly selective mechanism of action,7 with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.Tepotinibis currently under clinical investigation in NSCLC and not yet approved in any markets outside of Japan.Merck KGaA, Darmstadt, Germany is actively assessing the potential of investigating tepotinib in combination with novel therapies and in other tumor indications. Tepotinib is approved under the brand name TEPMETKO in Japan for the treatment of unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. The brand name TEPMETKO is not approved for use outside of Japan.

About bintrafusp alfa

Bintrafusp alfa (M7824), discovered in-house at Merck KGaA, Darmstadt, Germany, is a potential first-in-class investigational bifunctional fusion protein designed to simultaneously block two immunosuppressive pathways, TGF- and PD-L1, within the tumor microenvironment. This bifunctional approach is thought to control tumor growth by potentially restoring and enhancing anti-tumor responses.In preclinical studies, bintrafusp alfa has demonstrated antitumor activity both as monotherapy and in combination with chemotherapy. Based on its mechanism of action, bintrafusp alfa offers a potential targeted approach to addressing the underlying pathophysiology of difficult-to-treat cancers.

[emailprotected] is the global clinical trial program investigating the potential co-localized, dual inhibition of TGF- and PD-L1 with bintrafusp alfa (M7824) in multiple tumor types. Current clinical trial information can be found on the [emailprotected] website at http://www.intrapidclinicaltrials.com. To date, more than 850 patients with various types of solid tumors have been treated globally in the bintrafusp alfa [emailprotected] clinical development program.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribeto register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About EMD Serono, Inc.

EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt,Germany in the U.S. andCanada- is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,500 employees around the country with commercial, clinical and research operations based in the company's home state ofMassachusetts.www.emdserono.com.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of 16.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Contacts:

Media: Julissa Viana 781 206 5795

Investor Relations +49 6151 72-3321

SOURCE EMD Serono

See the rest here:
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - PRNewswire

Recommendation and review posted by Bethany Smith

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9pqrta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View post:
Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire

Recommendation and review posted by Bethany Smith

More than three months into the coronavirus pandemic, widely acknowledged shortcomings with testing continue to hamper the nations recovery. So when a team of microbiologists headed by Dr. Feng Zhang of the McGovern Institute at MIT and the Broad Institute reported this month that they had ironed out a protocol for a simple, cheap, point-of-care test that uses CRISPR to detect the virus, it was hailed as one of the most important contributions to fighting COVID-19.

Efforts to build and scale up a diagnostic have been beset by a number of snags, from a scarcity of chemicals called reagents and equipment to slow return of results. As officials debate how to safely reopen the country, those weaknesses would need to be rectified in a way where relaxing stay-at-home orders doesnt set off a viral rebound.

According to the Harvard Global Health Institute, in order to safely reopen the country and keep it open, we must ramp our testing rate from about a million per week to a million per day. But that remains a stretch by conventional means.

Enter CRISPR, the precision genome-editing technique that is anything but conventional.

Dr. Zhang and his colleagues harnessed a new type of CRISPR to build a test able to rapidly detect as few as 100 coronavirus particles in a swab or saliva sample, according to instructions for the new test, called STOPCovid, that they posted online. The teams focus has now shifted to proving that the test is safe and effective on a mass scale.

Like any diagnostic chemistry, we need to demonstrate that STOPCovid is accurate on a large enough cohort of patient samples to provide benefit, wrote Drs. Jonathan Gootenberg and Omar Abudayyeh, both of the McGovern Institute, in response to emailed questions. In addition, the current pandemic has made clear the need to scale to thousands or millions of tests, and solutions for that are necessary as well.

As to when the new diagnostic may be pressed into service against the novel coronavirus, Its hard to predict what the timeframe would be for a point-of-care or at-home test, the two noted. But given the need for these diagnostics, we would hope at latest by the end of the year.

That timeframe is possible because a prototype for a quick, easy, cheap and precise CRISPR-based diagnostic test had already existed. In 2017 Dr. Zhang and bioengineer Dr. James Collins published research showing that CRISPR could be trained to detect extremely low amounts of genetic material and was suitable for use during disease outbreaks. They dubbed this system Sherlock, for specific high-sensitivity enzymatic reporter unlocking.

Its from that earlier prototype that the new SARS-CoV-2 test takes its cue. STOP stands for Sherlock Testing in One Pot think multiple steps reduced to a single reaction in a tube. Its similar to DNA-targeting CRISPRs, like the well-known Cas9 system for DNA-editing of the human genome. Only this system has been reformulated to target strands of RNA, which are the building blocks of viruses.

Once a guide RNA molecule brings the Cas12 enzymes to the area of interest, the enzymes cut it in such a way that it generates a fluorescent readout. That readout is detectable, in much the same way home pregnancy tests pick up on pregnancy-related hormones.

Broadscale testing of the type afforded by STOPCovid would be integral to reopening the economy again, said Dr. Neville Sanjana, a genome engineer who was not involved in the CRISPR diagnostic research but whose lab, based at the New York Genome Center and NYU, is involved in several efforts using CRISPR, both COVID-related and non.

The CRISPR-based diagnostics do present a path forward not just to scaling up but to longitudinal sampling, continual sampling, said Dr. Sanjana, who, in addition to being a faculty member at the New York Genome Center, is also assistant professor of biology at New York University and of neuroscience and physiology at the NYU School of Medicine. Were only going to feel comfortable going back to work if not only do you know that your coworker was Covid-negative yesterday, but you know your coworker was Covid-negative last week and Covid-negative today if you have as many assurances as possible.

To fully appreciate why a CRISPR-based test might be a good fit in this situation requires a comparison to the standard COVID-19 test, which is based on a technology called qPCR. The qPCR tests work by detecting nucleic acids, like RNA, and amplifying them. In that sense, theyre similar to CRISPR-based tests.

However, thats where the similarities end.

The qPCR tests require a specialized piece of equipment combining a thermocycler (a machine that automatically cycles through multiple temperature changes) and a microscope. These machines are typically only found in labs and normally cost a few thousand dollars apiece. The other big limitation of qPCR is that the reagents needed to perform the test require cold storage.

CRISPR-based diagnostics, on the other hand, can assay the presence or absence of a nucleic acid at just one temperature. In addition, its been demonstrated also by Dr. Zhang and colleagues that its possible to freeze-dry CRISPR enzymes, obviating the need for cumbersome cold storage.

You dont need the microbiology lab. Instead, you maybe need a stove, said Sanjana.

One of the unique aspects of CRISPR is that it enables sensitive detection without requiring fancy equipment or refrigerated storage.

Reading the results is relatively simple, too. Whereas qPCR and PCR-based test results must be read out either using a microscope or something called agarose gel electrophoresis another lab mainstay the CRISPR-based assay for SARS-CoV-2 uses a lateral flow strip for readout, akin to a home pregnancy test.

A test strip is placed in a tube, and the presence of two lines indicates SARS-CoV-2. Results come in about an hour, the researchers say, with no special handling needed. A mobile phone app can analyze images captured by the phone camera to readout test results, they noted in their white paper.

That [kind of straightforward readout] would be an enabling technology, said Sanjana, even in places located close to a traditional lab.

Whats more, STOPCovid tested on a nasopharyngeal swab bested sensitivity and specificity rates of qPCR, according to Zhangs team (its been shown to work in saliva, too). His group has prepared reagents for 10,000 tests to make freely available to other researchers who want to evaluate its diagnostic use.

At least two other research groups are studying CRISPR technologys promise in diagnosing coronavirus. The FDA was suitably impressed with the test coming out of the Broad group, which is being commercialized through a company aptly named Sherlock, that the agency handed it an emergency use authorization this month. Meanwhile, Zhang is reportedly talking to would-be commercial partners about designing a device based on a disposable, single-use test cartridge, similar to a pregnancy test.

Thats the kind of thing we want, said Dr. Sanjana. If I had to think about what would be the ideal test, it would be something that would be dirt cheap, you could do it every single day, you could test yourself and your whole family, and youd get results instantly or close to instantly. This is what we need to go back to work safely.

Not to say that the CRISPR-based testing is the end-all-be-all, he added, but I think it can fill a very unique niche, even in places where you might have access to what you need to do qPCR-based tests. But the convenience would be greater and thus the adoption would be better.

Here is the original post:
A CRISPR-based, at-home COVID-19 test is set to arrive this year. Here's what you need to know - News - MM&M - Medical Marketing and Media

Recommendation and review posted by Bethany Smith

The recent outbreak of the COVID-19 (Coronavirus) pandemic has built and broken many value-grab opportunities for companies in the CRISPR and Cas Genes market. Gain full access on our latest analysis about COVID-19 and how companies in the CRISPR and Cas Genes market are capitalizing on new strategies to maintain stable revenue income. Look into our resourceful insights highlighting the impact of COVID-19 caused on the global market landscape.

Why Choose MRRSE Research?

Request Sample Report @https://www.mrrse.com/sample/17251?source=atm

The report on the global CRISPR and Cas Genes market published by Market Research Reports Search Engine(MRRSE) provides a clear understanding of the flight of the CRISPR and Cas Genes market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the CRISPR and Cas Genes market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the CRISPR and Cas Genes market are analyzed in the report.

The study reveals that the global CRISPR and Cas Genes market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the CRISPR and Cas Genes market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17251?source=atm

Key Takeaways of the Report:

CRISPR and Cas Genes Market Segmentation

By Region

The presented study throws light on the current and future prospects of the CRISPR and Cas Genes market in various geographies such as:

By Product Type

The report highlights the product adoption pattern of various products in the CRISPR and Cas Genes market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell Inc. These players are adopting organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and market share.

The global CRISPR and Cas genes market has been segmented as follows:

Global CRISPR and Cas Genes Market, by Product

Global CRISPR and Cas Genes Market, by Application

Global CRISPR and Cas Genes Market, by End-user

Global CRISPR and Cas Genes Market, by Region

Buy This Report @ https://www.mrrse.com/checkout/17251?source=atm

The report addresses the following doubts related to the CRISPR and Cas Genes market:

Here is the original post:
The impact of the coronavirus on the CRISPR and Cas Genes Market 2020:Key Insights, Drivers and Restraints, Opportunities and Challenges, Sales and...

Recommendation and review posted by Bethany Smith

After William Blair and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG yesterday and set a price target of $80.00. The companys shares closed last Friday at $61.09.

According to TipRanks.com, Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.8% and a 39.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $71.83, a 28.8% upside from current levels. In a report issued on May 6, Chardan Capital also reiterated a Buy rating on the stock.

See todays analyst top recommended stocks >>

The company has a one-year high of $74.00 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 967.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read this article:
Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row - Smarter Analyst

Recommendation and review posted by Bethany Smith

A new business intelligence report released by CMI with title Global CRISPR and CAS Gene Market Research Report 2020-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global CRISPR and CAS Gene Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Whats keeping Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Get Summery Of this Report:https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Market Overview of Global CRISPR and CAS Gene

If you are involved in the Global CRISPR and CAS Gene industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Detailed Segmentation:

By Product Type:Vector-based CasDNA-free CasGlobal CRISPR and CAS Gene Market, By Application:Genome EngineeringDisease modelsFunctional GenomicsKnockdown/activationOther Applications

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of CRISPR and CAS Gene

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this CRISPR and CAS Gene market

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

Get PDF brochure of this report: https://www.coherentmarketinsights.com/insight/request-pdf/2598

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (presentation)

Research methodology adopted by CMI

Request sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2598

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

Reasons to Purchase CRISPR and CAS Gene report is:

Gives a complete understanding of the CRISPR and CAS Gene Market to express competitor information, analysis, and insights to formulate effective RD strategies.

Collect data of the developing participants having the potentially profitable portfolio in this space and create effective counter-strategies to gain competitive benefits.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comPhone: US +1-206-701-6702/UK +44-020 8133 4027

Link:
CRISPR and CAS Gene Market to Witness Huge Growth by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio...

Recommendation and review posted by Bethany Smith

The shares of CRISPR Therapeutics AG (NASDAQ:CRSP) has been pegged with a rating of Hold by Stifel in its latest research note that was published on March 05, 2020. The Healthcare company has also assigned a $52 price target. Stifel wasnt the only research firm that published a report of CRISPR Therapeutics AG, with other equities research analysts also giving their opinion on the stock. Evercore ISI advised investors in its research note published on February 03, 2020, to In-line the CRSP stock while also putting a $52 price target. The stock had earned Outperform rating from William Blair Markets when it published its report on November 19, 2019. The stock was given Outperform rating by Oppenheimer in its report released on November 12, 2019, the day when the price target on the stock was placed at 65. Jefferies was of a view that CRSP is Buy in its latest report on August 01, 2019. Canaccord Genuity thinks that CRSP is worth Buy rating. This was contained in the firms report on July 26, 2019 in which the stocks price target was also moved to 72.

Amongst the analysts that rated the stock, 2 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 11 advised investors to purchase the stock. The price of the stock the last time has raised by 89.13% from its 52-Week high price while it is -17.45% than its 52-Week low price. A look at the stocks other technical shows that its 14-day RSI now stands at 66.89.

The shares of the company added by 9.32% during the trading session on Friday, reaching a low of $54.86 while ending the day at $61.09. During the trading session, a total of 1.03 million shares were traded which represents a -6.22% decline from the average session volume which is 0.97 million shares. CRSP had ended its last session trading at $55.88. CRISPR Therapeutics AG debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 16.90 CRSP 52-week low price stands at $32.30 while its 52-week high price is $74.00.

The company in its last quarterly report recorded -$1.15 earnings per share which is below the predicted by most analysts. The CRISPR Therapeutics AG generated 889.71 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.51 earnings per share. Compared to the same quarter last year, the firms revenue was up by 12.17%. CRISPR Therapeutics AG has the potential to record -4.51 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on May 15, 2020 where it informed investors and clients that Canada Goose Holdings Inc. (NYSE:GOOS) is now rated as Underperform. Even though the stock has been trading at $20.70/share, analysts expect it to down by -7.15% to reach $32.90/share. It started the day trading at $19.74 and traded between $18.52 and $19.22 throughout the trading session.

A look at its technical shows that GOOSs 50-day SMA is 20.58 while its 200-day SMA stands at 33.10. The stock has a high of $51.71 for the year while the low is $12.94. The stock, however, witnessed a rise in its short on 04/30/20. Compared to previous close which recorded 10.25 M shorted shares, the short percentage went lower by -6.05%, as 9.63M CRSP shares were shorted. At the moment, only 16.46% of Canada Goose Holdings Inc. shares were sold short. The companys P/E ratio currently sits at 28.14, while the P/B ratio is 9.99. The companys average trading volume currently stands at 2.23M shares, which means that the short-interest ratio is just 4.32 days. Over the past seven days, the company moved, with its shift of -15.74%. Looking further, the stock has dropped -38.00% over the past 90 days while it lost -44.79% over the last six months.

Morgan Stanley Asia Ltd. (Investm meanwhile bought more GOOS shares in the recently filed quarter, changing its stake to $162,992,259 worth of shares.

Following these latest developments, around 0.71% of Canada Goose Holdings Inc. stocks are owned by institutional investors and hedge funds.

Follow this link:
Mixed Analyst Attention: CRISPR Therapeutics AG (NASDAQ:CRSP), Canada Goose Holdings Inc. (NYSE:GOOS) - State Reviewer

Recommendation and review posted by Bethany Smith

This discovery may have clinical importance in management of heart failure.

This discovery may have clinical importance in management of heart failure.Many heart diseases are linked to oxidative stress, an overabundance of reactive oxygen species. The body reacts to reduce oxidative stress where the redox teeter-totter has gone too far up through production of endogenous antioxidants that reduce the reactive oxygen species. This balancing act is called redox homeostasis.

But what happens if the redox teeter-totter goes too far down, creating antioxidative stress, also known as reductive stress? Rajasekaran Namakkal-Soorappan, Ph.D., associate professor in the University of Alabama at Birmingham Department of Pathology, and colleagues have found that reductive stress, or RS/AS, is also pathological. This discovery, they say, may have clinical importance in management of heart failure.

They report that RS causes pathological heart enlargement and diastolic dysfunction in a mouse model. This study, published in the journal Antioxidants and Redox Signaling, was led by Namakkal-Soorappan and Pei Ping, Ph.D., David Geffen School of Medicine at the University of California-Los Angeles.

Antioxidant-based therapeutic approaches for human heart failure should consider a thorough evaluation of antioxidant levels before the treatment, they said. Our findings demonstrate that chronic RS is intolerable and adequate to induce heart failure.

The study used transgenic mice that had upregulated genes for antioxidants in the heart, which increased the amounts of antioxidant proteins and reduced glutathione, creating RS. One mouse line had low upregulation, and one had high upregulation, creating chronic low RS and chronic high RS, respectively, in the hearts of the mice.

The mice with high RS showed pathological heart changes called hypertrophic cardiomyopathy, and had an abnormally high heart ejection fraction and diastolic dysfunction at 6 months of age. Sixty percent of the high-RS mice died by 18 months of age.

The mice with low RS had normal survival rates, but they developed the heart changes at about 15 months of age, suggesting that even moderate RS can lead to irreversible damage in the heart over time.

Giving high-RS mice a chemical that blocked biosynthesis of glutathione, beginning at about 6 weeks of age, prevented RS and rescued the mice from pathological heart changes.

Gobinath Shanmugam, Ph.D., postdoctoral fellow in the UAB Department of Pathology, and Namakkal-Soorappan point out that a 2019 survey found about 77 percent of Americans are consuming dietary supplements every day, and within this group, about 58 percent are consuming antioxidants as multivitamins. Thus, a chronic consumption of antioxidant drugs by any individual without knowing their redox state might result in RS, which can induce pathology and slowly damage the heart.

In a related study, published in the journal Redox Biology, Namakkal-Soorappan looked at the impact of RS on myosatellite cells, which are also known as muscle stem cells. These cells, located near skeletal muscle fibers, are able to regenerate and differentiate into skeletal muscle after acute or chronic muscle injury. The regulation of myosatellite cells is of interest given the loss of skeletal muscle mass during aging or in chronic conditions like diabetes and AIDS.

Recently, Namakkal-Soorappan reported that tilting the redox teeter-totter to oxidative stress impaired regeneration of skeletal muscle. Now, in the Redox Biology paper, he has shown that tilting the redox to RS also causes significant inhibition of muscle satellite cell differentiation.

Rather than genetic manipulation to induce RS, as was done in the heart study, the researchers used the chemical sulforaphane or direct augmentation of intracellular glutathione to induce RS in cultured mouse myoblast cells. Both treatments inhibited myoblast differentiation. Finally, authors attempted to withdraw antioxidative stress by growing cells in medium without sulforaphane, which removes the RS and accelerates the differentiation. Namakkal-Soorappan and colleagues found that a pro-oxidative milieu, through a mild generation of reactive oxygen species, was required for myoblast differentiation.

The researchers also showed that genetic silencing of a negative regulator of the antioxidant genes also inhibited myoblast differentiation.

Co-authors with Namakkal-Soorappan and Ping, and first-author Shanmugam, in the Antioxidants and Redox Signaling study, Reductive stress causes pathological cardiac remodeling and diastolic dysfunction, are Silvio H. Litovsky and Rajesh Kumar Radhakrishnan, UAB Department of Pathology; Ding Wang, UCLA; Sellamuthu S. Gounder, Kevin Whitehead, Sarah Franklin and John R. Hoidal, University of Utah School of Medicine; Jolyn Fernandes and Dean P. Jones, Emory University, Atlanta, Georgia; Thomas W. Kensler, Fred Hutch Cancer Research Center, Seattle, Washington; Louis DellItalia, UAB Department of Medicine; Victor Darley-Usmar, UAB Department of Pathology; and E. Dale Abel, University of Iowa.

In the Redox Biology study, Reductive stress impairs myogenic differentiation, co-authors with Namakkal-Soorappan are Sandeep Balu Shelar, UAB Department of Pathology; Dean P. Jones, Emory University; and John R. Hoidal, University of Utah School of Medicine.

Support for both studies came from National Institutes of Health grants HL118067 and AG042860, American Heart Association grant BGIA 0865015F, the University of Utah, and UAB.

In the two studies, Namakkal-Soorappans name is listed as Namakkal S. Rajasekaran.

See the original post:
Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix

Recommendation and review posted by Bethany Smith

Telephone-based genetic counseling is just as useful as in-person meetings for those who would like to better understand and potentially reduce their risks of developing cancer, according to research presented May 13 in advance of the American Society of Clinical Oncology's (ASCO) virtual scientific program, to be held May 29 through 31.

The study indicates that remote forms of counseling, including telephone or real-time video to consult with a healthcare professional, can be a highly effective tool to provide preventive cancer care and genetic counseling, say the authors of the study, which was led by MD Anderson Cancer Center in Houston.

The use of remote healthcare services, ortelehealth, has soared in recent months due to the COVID-19 pandemic and the need for healthcare professionals and patients to find ways to communicate without risking transmission of the coronavirus.

The new study, which was performed prior to the pandemic, was designed to assess ways to make genetic testing more accessible and to validate the process of remote testing and counseling.

The study, dubbed MAGENTA (Making Genetic Testing Accessible)), is a national, randomized trial focusing on people at risk for breast cancer and ovarian cancer. Genetic counseling can be particularly helpful to assess the risks of these two cancers because there are identifiable gene mutations known to increase risk, such as the BRCA gene mutations.

More than a dozen other gene mutations including CHEK2, CDH1, andPTEN mutations are known to increase the risk of breast or ovarian cancer or both.

Genetic counseling and, if indicated, testing can help people understand their risk, determine whether other family members are at an increased risk, and trigger medical care to lower risk, such as more frequent cancer screenings, lifestyle changes, use of preventive medication, and even prophylactic surgery.

The study included nearly 4,000 women age 30 and older who had not had genetic counseling or genetic testing in the past and who either had breast or ovarian cancer themselves or had a family member with one of those cancers.

The participants received a genetic test and were assigned to receive either in-person counseling or telephone counseling. Those who received remote counseling received a genetic home test kit, which required providing a saliva sample in a tube and mailing it in.

Among those participants who completed genetic testing, 7.2 percent were found to have a genetic mutation that increased breast or ovarian cancer risk. Researchers reported no changes in the participants levels of anxiety and distress when receiving remote counseling compared with in-person counseling. In fact, those in the telephone counseling group were more likely to follow through with scheduling related medical care compared with those in the in-person counseling group.

The remote testing and education methods resulted in more follow-through in completing the testing than traditional genetic counseling, even though counseling was provided conveniently by phone, saysEElizabeth M. Swisher, MD, director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance and coleader of the Stand Up to Cancer Ovarian CancerNational Ovarian Cancer Coalition Dream Team, which sponsored the study.

Our results provide a foundation for electronic access to testing that goes beyond telehealth access, with equivalent patient outcomes less hassle for patients and less cost to the healthcare system, says Dr. Swisher.

RELATED: COVID-19 Warriors: Stories From the Front Lines of the Pandemic

A randomized, phase 2 clinical trial shows that an approach called transoral resection with low-dose radiation is safe and effective for some people with oropharynx (throat) cancer. The approach is easier to tolerate and leaves patients with fewer long-term side effects related to radiation.

The study of 353 people compared several approaches to throat cancer caused by human papillomavirus, which accounts for about 70 percent of the disease, according to the Centers for Disease Control and Prevention. Researchers examined pathological biomarkers unique to each patient, such as the extent of cancer in the lymph nodes and tumor characteristics.

Following surgery using a transoral robotic approach (TORS), people with a low risk of recurrence were observed. Those with an intermediate risk of recurrence received lower-dose radiation. People at a high risk of recurrence were assigned to the standard dose of radiation plus chemotherapy.

The study showed that for intermediate-risk patients, a reduced dose of radiation after surgery without chemotherapy appears sufficient. Less radiation typically preserves a patients throat function and reduces pain, the authors note.

The group receiving a reduced dose of radiation also had better outcomes than the group receiving high-dose radiation plus chemotherapy. People with low-risk disease had low recurrence rates after two years.

The study showed the value of stratifying patients according to risk and that the TORS surgical approach followed by low-dose radiation is safe and effective in people with intermediate-risk, locally advanced throat cancer, says lead investigator Robert L. Ferris, MD, PhD, director of theHillman Cancer Center at the University of Pittsburgh Medical Center and a surgical oncologist specializing in head and neck cancer.

"These results present a promising deintensification approach," he says.

RELATED: How Will COVID-19 Affect Cancer Research?

About 25 percent of all people with cancer taking oral chemotherapy medications also take herbal supplements, according to research from the University of Rhode Island. Assessing the use of over-the-counter herbal supplements is important because some substances may interact with oral chemotherapy agents, the authors say.

The study of 187 people taking oral chemotherapy drugs found that 24 percent were also taking herbal dietary supplements. The most frequently used supplements were melatonin and marijuana orcannabidiol oil. The authors recommend that people taking oral chemotherapy consult with an oncology pharmacist to prevent drug interactions and maximize the effectiveness of oral chemotherapy.

Federal health officials also recommend that people being treated for cancer consult with their healthcare providers before using any complementary health approach, such as using dietary supplements. According to the National Center for Complementary and Integrative Health, only about 15 percent of people being treated for cancer who use herbal supplements discuss their usage with their healthcare providers.

RELATED: Can You Overdose on Melatonin? How to Determine the Right Dosage for You

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) with limited chemotherapy appears to prolong overall survival as a first-line treatment for people with metastatic non-small cell lung cancer (NSCLC). The study suggests that adding limited chemotherapy to the combination of Opdivo and Yervoy may reduce the risk of the disease progressing when its in the early stage.

A previous study, CheckMate-227, showed the value of the immunotherapy combination as a first-line treatment for NSCLC. Opdivo is a type of immunotherapy known as a PD-1 inhibitor, while Yervoy is a category of drug known as a CTLA-4 inhibitor.

The new study, called CheckMate-9LA, was designed to assess the value of adding chemotherapy to the combination. The research presented at ASCO is the first release of results from CheckMate-9LA.

The phase 3 trial showed that Opdivo and Yervoy given together with two cycles of chemotherapy reduced the risk of death by 31 percent compared with chemotherapy alone after at least eight months of follow-up. After more than a year of follow-up, the combination plus chemotherapy showed continued improvements in overall survival compared with chemotherapy alone.

Adding a limited course of chemotherapy may help mitigate the risk of early disease progression, saysMartin Reck, MD, PhD, the studys lead investigator and an oncologist at the Lung Clinic Grosshansdorf in Germany. As the data become more mature, I see the potential for an improving survival benefit over time.

RELATED: Smokers Who Quit Before Lung Cancer Diagnosis Are More Likely to Survive the Disease

See the original post:
Genetic Counseling, New Treatments for Lung Cancer and Throat Cancer, and More From ASCO's Annual Meeting - Everyday Health

Recommendation and review posted by Bethany Smith

Magnifier Research has recently published a research report titled Global DTC Genetic Testing Market Size, Status and Forecast 2020-2026 explores the ongoing outlook in global and key regions from the perspective of major players, countries, product types and end industries. The report comprises and forecast values for a versatile understanding. Then, the report offers the perspective of major players, countries, product types and end industries. The research also analyzes top players in the global market and divides the market into several parameters. It presents the profile reviews of the leading participants, their overall market shares in the global DTC Genetic Testing market, business strategies they have adopted, and the latest developments in their respective businesses.

Market Analysis:

The report gives an evaluation of various drivers, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments. The report analyzes the scope of different segments and applications that can potentially influence the global DTC Genetic Testing market in the future. Diverse topics discovered in the report includes regional market scope, product-market various applications, market size according to a specific product, sales, and revenue by region, production cost analysis, supply chain, market influencing factors analysis, market size estimates, a look at the target market, an analysis of competition.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/29799/request-sample

Major key players of the market are: 23andMe, Ancestry, Color, EasyDNA, Family Tree DNAGene by Gene, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA, MapMyGenome, MyHeritage, Pathway Genomics,

For a comprehensive understanding of market dynamics, the market is analyzed across key geographies namely: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

This report segments the global market on the basis of types are:

On the basis of application, the global market is segmented into: Carrier Testing, Predictive Testing, Ancestry and Relationship Testing, Nutrigenomics Testing, Other

Furthermore, the global DTC Genetic Testing research report has mentioned key manufacturers strategic enterprises and provides a brief about their structure. Analysts have also mentioned the research and development conditions of these companies and their provided complete information about their existing products. The report has figured out key factors as per segments and it includes price, value, availability, features, financing, upgrades or returns policies, and customer service. Most noteworthy, this market analysis will help you find market dark spots in the market.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-dtc-genetic-testing-market-size-status-and-29799.html

Projections:

The report offers thoughtful forecasting. It also explains the consumption behaviour of users. Here, analysts have shown real stats and numbers. These bottom-up projections will explain how your marketing and sales efforts will enable you to get a certain percentage of the market. This report study describes the projected growth of the global DTC Genetic Testing market for approaching years from 2020 to 2026.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

Read more here:
COVID-19 IMPACT ON DTC Genetic Testing Market | VOLUME, ANALYSIS, FUTURE PREDICTION, INDUSTRY OVERVIEW AND FORECAST 2026 - Surfacing Magazine

Recommendation and review posted by Bethany Smith

When I left my job in February to focus on trying for a baby, I was full of hope. This was going to be the year Id get pregnant. Instead, Im in limbo, the possibility of becoming a mother seeming further and further away.

My husband Matthew and I have always wanted a family. Weve been together for 11 years, but because wed been teaching abroad, we waited until we moved back to the UK to start trying. In 2017, when we were settled in North Yorkshire and both in our mid-30s, I came off the Pill, but after six months nothing was happening.

My GP told me to enjoy trying to conceive and that everything was fine. But by January 2019 we were worried so had our first IVF consultation. The consultant said my FSH [follicle-stimulating hormone] results were concerning, as were the results of my AMH [anti-Mllerian hormone] test, which confirmed that I didnt have many eggs left. It was the first time we were told there was a problem. I cried all the way home.

We started IVF last May, but my body didnt create enough follicles [ovarian sacs that release eggs for fertilisation] to proceed to the egg-collection phase, so we cancelled the cycle and began again in October. It was a difficult time. The doctors upped my medication and the combination of the hormones and the desire for it to be a success made me anxious. Teaching had been my life, but suddenly it felt like it was getting in the way.

Four eggs were collected, and grew into two embryos. But by the time I was due to have them transferred into my uterus, the embryologist called with awful news: they had stopped growing. I couldnt speak, I just started crying. Matthew and I spent the rest of the day in tears that was our one free NHS cycle.

We looked for a private clinic we could afford, opting for Serum IVF in Athens, which suggested we do two lightly stimulated cycles. The cost, including flights and hotel, came to 6,000, compared to 8,000 back home for just one cycle. On 2 March, we flew to Athens. At the clinic, the doctors spotted a huge polyp in my uterus, so after my egg collection, I had it removed. I later found out that theyd only collected one egg but it was a good one.

After we returned home, we found out that our embryo had developed into a blastocyst, a more advanced embryo of very good quality. It was frozen for use at a later date. I felt calm and positive, and despite coronavirus emerging in Europe, we still thought wed be able to return for our second cycle.

But a few days later the clinic told us it was following strict new guidelines not to proceed with any transfers until further notice. I was in total despair. After two and a half years of trying and getting so close, it had all been taken away. It felt so cruel.

Read more here:
My chances of having a baby are fading away due to coronavirus - Telegraph.co.uk

Recommendation and review posted by Bethany Smith

The test wont tell you other factors that can affect the reproductive system like Endometriosis, Uterine Fibroids, cysts, infections or stress. But it can indicate Polycystic ovarian syndrome (PCOS).

And while the AMH test indicates the number of eggs, it will not deliver the holy grail of fertility information, the QUALITY of eggs. No, the only way to test quality is to fertilize the eggs to see if embryos form. So basically, to make a baby.

If youre not ready for that, the AMH test is at least some information.

Male fertility is so blunt: all the main bits on the outside. A new load of sperm regenerates every 64 days. One explosion in a cup and a fertility specialist has most of the picture.

But a womans fertility is an elusive and complex force of nature. She is with us for a fleeting moment and the further we move into our thirties, the more cryptic she becomes.

My first peek under the veil of my own fertility took three GPs before I was given the AMH test. My result was 11.2. Its in the lower percentile range, but normal for my age. If the results came back abnormally low, theres no question I wouldve reprioritised a baby sooner rather than later.

And if the test does identify a low egg count, its best to know at 28 rather than 35 right?

The cheap, non-invasive AMH test is not subsidised by Medicare, but IVF is. Why fund a last resort fertility procedure but not a simple test that can identify a factor to consider way before IVF is on the table?

Women should be trusted by the medical community to understand the results and not presumed to misuse or misinterpret the information. And this argument should not be used to hold the test back from women like myself just looking for a little more information.

Listen to Before the Bump, Mamamias fertility podcast. Post continues below.

For me, having a normal AMH result didnt make me prioritise a baby but it didnt make me feel less panicked either. Instead, I formed the following logic: if I had a normal egg pool for my age, it was statistically likely Id also take a normal amount of time to fall pregnant.

If I stopped using contraception methods, I anticipated three to six months at least. It could even take a year, I thought.

I wasnt actively trying and I rarely had sex because my fianc worked away. In a calendar year, there were only five months his presence would line-up with my cycle.

And yet, I fell pregnant at the first possible chance after a single night with him. Pregnant with twins.

Read more:
'There's a test to help predict fertility. But at age 34, my GP wouldn't give it to me.' - Mamamia

Recommendation and review posted by Bethany Smith

A NEW promotional body has been set up to bring together the marketing of all types of Mule sheep.

The Mule Group aims to promote the 'adaptability, profitability and ideal mothering characteristics' of females from each of the five main Mule Societies Scotch Mules, North of England Mules, Welsh Mules, Cheviot Mules and Highland Mules.

While each society has always worked as an individual association and will continue to do so, there is a commonality between them in that they all share the same sire in the Bluefaced Leicester and the Bluefaced Leicester Association is supporting the new group to promote the overall message that Mules are the UK's 'Number One commercial breeding female' and ensure marketing of the cross-breds reaches its full potential.

It is estimated that 400,000 mule females are sold annually, with enough breeders involved to give the Mule Group a combined membership of 3500.

Newly appointed chairman of the group, Derek Hall, of the Firth flock, Penicuik, is confident the new initiative will increase demand for both the females and the Bluefaced Leicester breed.

It is important we challenge our competitors and the only way we can do that is to join forces under the one umbrella to promote the attributes of Mules," said Mr Hall. "There is variation in the different types of Mules, however, their key traits of hybrid vigour and mothering ability are all similar.

The message we want to push is that the Mule is adaptable and ultimately ensures profitability to any flock," he said. The Mule is the key link in the sheep industry that brings the hills and uplands, right down to the lowlands together. It is now our challenge to cooperate with each other to ensure the best marketing of the mighty Mule!"

According to Mr Hall, the hybrid vigour of the Mule produces a breeding female that is hardier, with 'amazing' mothering abilities, that can perform well in many different systems.

The hybrid vigour comes from the uniqueness of the Bluefaced Leicester, which is genetically, a different breed of sheep to all others, consequently, the genetics from the Blue provide a higher level of hybrid vigour than any other breed," he asserted. "This in turn ensures a hardy cross-bred female with attributes that outperform that of any other breed or cross."

I am really excited to see where The Mule Group takes us because there is so much room to develop and expand the breeding potential of the Mule and everyone seems to be up for the challenge. Whatever the question, the answer is the Mule!"

See original here:
Mule societies pull together - The Scottish Farmer

Recommendation and review posted by Bethany Smith

More men have died from COVID-19, the disease caused by the novel coronavirus, across the world than women except in Canada.

According to the latest data from the Public Health Agency of Canada, more women have been diagnosed with COVID-19 than men, and more women have died as a result. As of May 15, 55 per cent of confirmed cases of COVID-19 are women, and 45 per cent are men.

Of the total deaths, 53 per cent are women and 47 per cent are men.

READ MORE: How many people is coronavirus really killing? Ontarios data cant tell us

The provinces with the highest number of cases and deaths Quebec and Ontario also have starker gaps between the genders, according to daily provincial epidemiologic summaries.

In Ontario, currently around 57 per cent of those infected are women, while close to 42 per cent are men. Similarly, in Quebec, close to 60 per cent of confirmed COVID-19 cases are women and around 54 per cent of deaths are also women.

This kind of data stands out from other countries who track coronavirus cases, as the vast majority have had more men than women die of COVID-19 since the emergence of the virus, according to Global Health 50/50, an organization out of the UCL Centre for Gender and Global Health in London, England.

Its difficult to discern why women are being more affected by COVID-19 in Canada, but there are several factors that could impact how the virus impacts different genders, says Colin Furness, an epidemiologist at the University of Toronto who specializes in infection control.

One possible reason could be because there are more female residents in Canadas long-term care homes, where the brunt of the cases and deaths in Canada are concentrated, Furness said.

READ MORE: Coronavirus numbers miss some deaths, experts warn. Heres why

Eighty-two per cent of Canadas COVID-19-related deaths have been in nursing homes, according to the National Institute on Aging.

Because of life expectancy differences, you are going to have more women represented in , Furness said, pointing out that Canadian women have higher life expectancies than men.

Data published in 2018 by Statistics Canada found that women were more likely to be widowed than men, and were more likely to be living in a nursing home or seniors residence.

Other countries are not seeing their long-term care homes ravaged by COVID-19 to the extent that Canada has. A study by the International Long-Term Care Policy Network published this month found that compared to 14 other countries, Canada had the most COVID-19-related deaths in long-term care.

Along with a higher representation in nursing homes, women are also more likely to work in caring professions that involve a lot of interaction with other people, Furness said.

This includes jobs like personal support workers (PSWs), like those who work in long-term care homes, he said. A recent study on PSWs in Canada found that workers are largely women and people of colour and/or immigrants.

READ MORE: Canadas lack of race-based COVID-19 data hurting Black Canadians: experts

A report published in February by the Ontario Health Coalition found that Ontario is facing a shortage of PSWs as many leave the profession due to being overworked, underpaid or injured on the job.

Last month, after a second PSW in Ontario died due to COVID-19, the union representing health care workers across the province blamed their deaths due to a lack of available personal protective equipment (PPE).

A report by Global News in April also found that long-term care homes across the country are struggling to access PPE.

Its also important to assess exactly which women are being impacted by COVID-19, said Suzanne Sicchia, an associate professor at the Interdisciplinary Centre for Health and Society at the University of Toronto Scarborough.

If data on race and socioeconomic status is collected, its likely to show women of colour are being disproportionately impacted, she said. More women of colour are employed as personal support workers in Canada, and research has found that people of colour often have worse health outcomes.

Canada should also be collecting data when it comes to the care work women do, personally and professionally, she said.

READ MORE: Coronavirus: 3rd Ontario personal support worker dies from COVID-19

Paid or unpaid, womens care work, for the sick and elderly at home, in their extended family, in their communities, is another possible source of elevated risk of infection, Sicchia said.

Many often think health is shaped by lifestyle choices or genetics, which are important. But its crucial to remember there are a multitude of other factors that shape the health of individuals or populations including income, employment, social status and racism, Sicchia said.

While more women in long-term care along with the number of women working as care providers are factors, its difficult to make concrete assessments without consistent data being collected by governments, Sicchia said.

Undoubtedly there are other determinants at play, and this is why more research and the collection of race-based data and data on other intersecting determinants of health is so important.

Questions about COVID-19? Here are some things you need to know:

Symptomscan include fever, cough and difficulty breathing very similar to a cold or flu. Some people can develop a more severe illness. People most at risk of this include older adults and people with severe chronic medical conditions like heart, lung or kidney disease. If you develop symptoms,contact public health authorities.

Toprevent the virus from spreading, experts recommend frequent handwashing and coughing into your sleeve. They also recommend minimizing contact with others, staying home as much as possible and maintaining a distance of two metres from other people if you go out.

For full COVID-19 coverage from Global News,click here.

2020Global News, a division of Corus Entertainment Inc.

Originally posted here:
More Canadian women have COVID-19 and are dying as a result. Here's some possible reasons why - q107.com

Recommendation and review posted by Bethany Smith

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will take place from June 22 to 24, 2020.

Session information is available online via the Annual Meeting Itinerary Planner through the AACR website at http://www.aacr.org.

Title: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors Session Title: Adoptive Cell Therapy 1 E-Poster Number: 879 Abstract Number: 3338

Title: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro Session Title: Adoptive Cell Therapy 1 E-Poster Number: 880 Abstract Number: 4647

Title: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors Session Title: Adoptive Cell Therapy 3 E-Poster Number: 3243 Abstract Number: 6231

Title: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells Session Title: Adoptive Cell Therapy 5 E-Poster Number: 6595 Abstract Number: 3308

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Investor Contact: Susan Kim +1 617-307-7503 susan.kim@crisprtx.com

CRISPR Media Contact: Rachel Eides WCG on behalf of CRISPR +1 617-337-4167 reides@wcgworld.com

More here:
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting - Stockhouse

Recommendation and review posted by Bethany Smith

A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration (FDA). It was developed by FKD Therapies Oy with the close collaboration of the Society of Urologic Oncology Clinical Trials Consortium in a novel industry/professional society partnership.

Originally, the therapy nadofaragene firadenovec (rAd-IFN/Syn3), since dubbed INSTILADRIN was developed in the lab of Colin P.N. Dinney, M.D., chairman, department of urology, division of surgery, University of Texas MD Anderson Cancer Center, Houston, and co-founder of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), which was critical in conducting the clinical trials.

As Dinney recalled, I developed this drug from preclinical to Phase I with Schering-Plough Corp. Then Schering was bought by Merck, which decided not to develop it.

That was around 2009, when the financial crisis was constraining research budgets and relegating many urologists to procedures.

To ensure that urologists retained awareness of and access to research opportunities, Dinney co-founded SUO-CTC, a network of approximately 400 academic and private practice urologists and 200 clinical sites. It works as an independent partner and consultant with biopharmaceutical companies to identify patients and sites for clinical trials, review clinical trial protocols, and meet with investigators and their collaborators to improve clinical trials.

This early, active involvement enables urologists to identify additional opportunities for companies while also expanding research opportunities for its urologist members. In addition to bladder cancer trials, the SUO-CTC also collaborates in partnership with pharmaceutical and biotechnology companies to develop and conduct trials for prostate cancer and renal cancer.

Its a very lean organization that offers enormous advantages to its pharma partners, Gennady Bratslavsky, M.D., told BioSpace. Its expertise encompasses many urologic sub-specialties including, but not limited to, sequencing and biomarkers, and insights from practicing physicians and academic experts. By providing this expertise early, we become an intellectual partner, which is a unique approach.

The development of nadofaragene firadenovec is a prime example of an effective collaboration between the SUO-CTC and pharma to develop a novel therapeutic that addresses an unmet need for patients with bladder cancer," Bratslavsky said.

When the SUO-CTC was formed, however, it started at ground zero.

We needed a trial to jumpstart the activity of the bladder cancer committee, and I had discussed nadofaragene firadenovec with the president of FKD Therapies Oy, Dinney said.

Not only did Dinney discuss his Phase I data, but he also discussed a particular patient. I had a patient with Alzheimers disease with high-grade non-muscle-invasive bladder cancer who had not responded to BCG therapy. His wife felt surgery was not a good solution because of his Alzheimers, Dinney said. He enrolled the man into a trial, and administered one of the higher doses. He remained disease-free until he died of Alzheimers four years later.

FKD licensed the therapy and Dinney negotiated for the SUO-CTC to have exclusive control of the trial sites. The organization recruited 13 sites from among its members for Phase II trials, and quickly enrolled patients. Larger Phase III trials also were recruited quickly and with favorable results.

"This treatment is truly a game-changer and adds a powerful new intravesical therapy for patients with Bacillus Calmette-Gurin (BCG) unresponsive bladder cancer," Dr. Michael Cookson, president of the Society of Urologic Oncology (SUO), said in a statement.

Specifically, INSTILADRIN is designed for patients with high-grade non-muscle-invasive bladder cancers. The therapy is an adenovirus vector-mediated interferon alfa-2b gene therapy. It was granted Breakthrough Therapy designation by the FDA. Industry watchers say it has the potential to compete with Mercks Keytruda, which was approved in January for the same condition.

Approximately 81,000 people inthe United Statesare diagnosed with bladder cancer every year, according to the American Cancer Society, making it one of the most common cancers. It also is one of the deadliest cancers, claiming nearly 18,000 lives in the U.S. this year alone.

The gene therapy is administered to patients via a catheter, directly into the bladder, once every three months. In trials, it helped the body produce high quantities of a protein that fights the cancer. In the Phase III trial, 53% of patients achieved a complete response as early as three months, and 24% at 12 months. In patients with papillary disease, 73% achieved high-grade recurrence free (HGRF) survival at three months and 44% at 12 months.

INSTILADRIN uses an adenoviral vector to deliver the gene to the cells of the bladder wall, where breaks down and releases its DNA including the interferon gene. That gene is taken into the nucleus and transcribed, ultimately resulting into the secretion of high quantities of interferon alfa-2b proteins being released into the microenvironment of the tumor.

Now, were waiting for approval from the FDA and looking at opportunities to expand indications. Discussions are ongoing, Dinney said. The SUO-CTC also is considering trials to introduce the drug earlier in the course of the disease, as well as including it in combination therapies. His own lab but, as yet, not the SUO-CTC is investigating a companion diagnostic for early applications.

FKD, for its part, led the development, manufacturing and regulatory submission efforts. Assuming the FDA approves INSTILADRIN, FKD plans to license the gene therapy to FerGENE for commercialization in the U.S. and to advance global development.

Here is the original post:
Game-Changing Gene Therapy a Joint Effort by Urologist Consortium and FKD Therapies - BioSpace

Recommendation and review posted by Bethany Smith

Everybody wants to be fit. But not everybody wants to put in the effort to get there.

Who has time to spend long hours at the gym and eating right is such a bore. What if we told you that you could get ripped without exercising and eating whatever you wanted.

RELATED:EXERCISE IS THE BEST WAY TO KEEP THE POUNDS OFF, SAYS NEW STUDY

This is whata team at Washington University in St. Louis medical school achieved with mice in test trials. They created a gene therapy that when given to mice allowed them to build muscle mass and reduce obesity even while eating a diet high in fat and not exercising.

How did it work? The therapytargeted a gene called FST, which makes a protein called follistatin. Follistatin blocks a protein called myostatin, which stops muscle growth to ensure muscles dont get too large.

The researchers injected a virus carrying a healthy FST geneintoeight-week-old mice. They then observed the mice over a period of 18 weeks.

What they found was nothing short of impressive. The mice's muscle mass and strength more than doubled and they experienced reduced damage related to osteoarthritis and less inflammation in their joints.

"Regardless of diet, mice receiving FST gene therapy were protected from post-traumatic OA and bone remodeling induced by joint injury. Together, these findings suggest that FST gene therapy may provide a multifactorial therapeutic approach for injury-induced OA and metabolic inflammation in obesity," wrote the researchers in their paper.

Last but not least, the researchers were worried that the muscle growth caused by the therapy could hurt the heart. However, the study revealed that the heart function and cardiovascular health of treated mice actually improved.

If the therapy can be adapted to work for humans both its appeal and its applications would be limitless. The research was published in Science Advances.

Here is the original post:
New Gene Therapy Promises You Will Get Ripped Without Stepping in a Gym - Interesting Engineering

Recommendation and review posted by Bethany Smith

PHENOMENAL WOMEN SCIENCE & RESEARCH

The San Diego Union-Tribune and the Womens Museum of California are celebrating a century of female achievement in San Diego to mark the 100th year of womens suffrage in America.

The second installment of this series pays tribute to pioneering female scientists and researchers who pushed boundaries in exploring our world and beyond and helped cultivate new generations of curious thinkers.

Spotlighted is Sally Ride, the first U.S. woman in space, who encouraged girls interest in science with her namesake educational program, Sally Ride Science, based at UC San Diego. Here are 11 other women in science and research you should know.

Margaret Burbidge

(U-T file)

A lot of people told Margaret Burbidge she was invading a mans world in the late 1930s when she took her first steps toward becoming an astronomer. She was undeterred even though many key telescopes were off-limits to women. Burbidge pushed through the sexism and became one of the most influential astronomers of her era, largely due to her insights about the chemical composition of stars. Her work helped scientists figure out how stars are made and earned her the nickname Lady Stardust. She also helped to develop the Hubble Space Telescope. And in 1962, she became a founding faculty member at UC San Diego, where she continued research that would later earn her the National Medal of Science. Burbidge died on April 5 at the age of 100.

Karen Nelson

(Howard Lipin/The San Diego Union-Tribune)

Karen Nelson was an early bloomer. At age 7, she joined fellow students in studying how nutrients and sunlight affect the growth of plants. The experiment stoked her interest in science. She went on to become a Cornell-trained physiologist who specializes in the study of the human microbiome the genetic material found in all of the micro-organisms that live in and on our bodies. Nelson led the first group of scientists in publishing the first major paper on the human microbiome. The paper spotlighted an obscure area of research that is now regarded as indispensable to understanding and treating everything from diabetes to multiple sclerosis to depression. Nelson today serves as president of the J. Craig Venter Institute, the renowned research center in La Jolla.

The UC San Diego graduate floated out of an airlock and into history in October as a member of the first all-female team of spacewalkers. The 42 year-old astronaut achieved the fete from the International Space Station, during a six-month mission in which she also conducted research thats meant to help astronauts stay safe and healthy on trips to the moon and Mars. Meir also became a popular host of space-to-Earth broadcast interviews, including an especially poignant one with TV host Stephen Colbert. And she appeared on camera to give earthlings who were sheltering at home from the coronavirus lots of advice about how to live in isolation. Her future could be even brighter she is among the astronauts NASA will consider as crew members for missions to the moon.

Ellen Ochoa

(Cindy Lubke Romero/The San Diego Union-Tribune)

Theres a word that often appears immediately after Ellen Ochoas name: first. In 1991, she became the worlds first Hispanic female astronaut. Two years later, she became the first Hispanic woman to travel in space, streaking into orbit aboard the shuttle Discovery. In 1999, she was a member of the first shuttle crew to dock with the International Space Station. In 2013 Ochoa, who grew up in La Mesa and graduated from San Diego State University, became the first Hispanic to be appointed director of NASAs Johnson Space Center. In 2017, she was inducted into the U.S. Astronaut Hall of Fame. A year later, she retired from NASA, capping a career that spanned nearly three decades.

Maria Goeppert-Mayer

(Evening Tribune)

When it was founded in 1960, UC San Diego quickly hired a handful of renowned professors to signal other faculty that La Jolla was the place to be. The first recruits included Maria Goeppert-Mayer, a German-born theoretical physicist whose discoveries about the nucleus of atoms would help revolutionize everything from weaponry to power generation. Her contribution earned her a share of the 1963 Nobel Prize in physics. She was the first woman in the U.S. to win that prize. The San Diego Union-Tribune responded with a now-infamous headline: S.D. Mother Wins Nobel Physics Prize. Fifty-five years would pass before another woman won the Nobel in physics.

Olivia Graeve

(Courtesy of UC San Diego)

When astronauts return to the moon, they may be flying in a spacecraft made safer by Olivia Graeve. The UC San Diego engineer designs new materials that are meant to withstand extreme environments. She developed and tested an extraordinarily strong type of steel, providing a possible material for everything from spacecraft to body armor. The work occurs at the Cali-Baja Center for Resilient Materials and Systems, which Graeve founded after she became UCSDs first Latina engineering professor. In the summer, the Tijuana native also brings students from Mexico and the U.S. to campus to conduct research, helping cultivate new generations of engineers.

Flossie Wong-Staal

(Koji Sasahara/AP)

Its impossible to count how many lives shes saved, but the number is enormous. Flossie Wong-Staal helped identify the cause of AIDS in 1983 while working at the National Cancer Institute. A short time later, she became the first scientist to clone HIV, then finished mapping the virus genetically. In 1990, Wong-Staal joined the UC San Diego faculty, doing landmark research that has helped fight HIV/AIDS. She also helped turn UCSDs Center for AIDS Research into a research power, and greatly advanced the field of gene therapy. The Chinese-American virologist retired from UCSD in 2002 but has remained active in science and was inducted into the National Womens Hall of Fame in 2019.

Ayana Elizabeth Johnson

(Evan Agostini/Invision/AP)

Not long ago, the wondrous Caribbean island of Barbuda did little to protect its coral reefs and manage its fish populations. Today it does a great deal through programs that Ayana Elizabeth Johnson helped to shape after she earned a doctorate at UC San Diegos Scripps Institution of Oceanography. It was a first step in her rapid rise as an influential voice in sustainable fishing and ocean conservation. Johnson went on to found and lead Ocean Collectiv, a La Jolla conservation consultancy. She also founded the Urban Ocean Lab, a think tank that helps coastal cities. And she played a key role in organizing the 2017 March for Science, which drew more than 1 million participants worldwide.

Balboa Park is so lush its hard to believe it was once a bland patch of land. Many people infused it with life. But none were more important than Kate Sessions, a botanist and horticulturalist who leased part of the park as a growing field in the late 1800s. Sessions planted a variety of trees, ranging from oak to cypress to eucalyptus. She also brought in jacaranda, and helped found the San Diego Floral Association. Her work earned Sessions the nickname Mother of Balboa Park. The honor was about more than beauty. Sessions also studied plants and chronicled how they grew and changed, bringing her worldwide attention in the scientific community. In 1939, the year before she died, the American Genetic Association honored Sessions with the Frank N. Meyer medal, one of the most coveted honors in plant genetics.

Shirley Meng

(David Baillot/UCSD)

Everyone knows that batteries die. But were you aware that they first become sick? Thats the word that Shirley Meng uses to describe what happens when batteries stop holding a charge. It is a poorly understood process. But Meng has been making important discoveries about the phenomenon at UC San Diego, where she is director of the Sustainable Power and Energy Center. Meng, a nano-engineer, specializes in creating new tools and techniques for visualizing, in real-time, whats happening as a battery fails. Her work is meant to improve everything from smartphone service to the range of self-driving cars. Meng who is known as the battery doctor also founded Super 8 Technologies, a company that is developing battery technology that could be used by the military and in space exploration.

Carol Padden

(Sandy Huffaker)

Some linguists used to pointedly question whether American Sign Language, or ASL, is a genuine language. Padden helped establish that ASL is not only legitimate, but that it is a very precise, complex and expressive way of communicating. Padden, who is deaf, has done similar work on Al-Sayyid Bedouin Sign Language. Shes made her contributions as a linguistics researcher and communications professor at UC San Diego. She also is dean of the Division of Social Sciences, UCSDs largest program. In 2010, Padden was honored for her work by being named a MacArthur Genius Fellow. She continues to operate a research lab, something rarely done by high-ranking university administrators.

Sources: UC San Diego, San Diego State University, NASA, J. Craig Venter Institute, Wikipedia, MacArthur Foundation, New York Times, Los Angeles Times, San Diego Union-Tribune

Read the original post:
Phenomenal San Diego women in science and research - The San Diego Union-Tribune

Recommendation and review posted by Bethany Smith

PharmaSphere: Emerging Biotechnologies-Gene Therapy market gives us the acute prediction regarding sales and trends:The current report focuses on the impact of Covid-19 on PharmaSphere: Emerging Biotechnologies-Gene Therapy market industry. This report covers all the important areas like how the key players are enhancing their activities for their survival in the worldwide PharmaSphere: Emerging Biotechnologies-Gene Therapy market business. Graphs and flowcharts are being used for analyzing the information to be acceptable.

Key player focused on this market are: Advantagene, Amarna Therapeutics, AnGes MG, Inc., Applied Genetic Technologies Corporation, AskBio, Avalanche, Bluebird bio, Celladon Corporation, Dimension Therapeutics, American Gene Technologies International Inc,

Download Special samples With the effect of COVID19@: https://www.regalintelligence.com/request-covid19-global-insights/88714

PharmaSphere: Emerging Biotechnologies-Gene Therapy research study depicts the constantly changing trends and growth in the market with valued CAGR (compounded annual growth rate) in their forecast including all the factors responsible for the changed performance, growth evaluation and profitability in the market business.

Key points on which report focuses are:

Providing acute information.

Professional study for the period 2020-2023a.

Details of upstream raw materials, downstream demand and production value.

Market growth factors.

Market segmentation:

Basis of segmentation: Types of products, application and region.

By Type: Type 1, Type 2

Significant PharmaSphere: Emerging Biotechnologies-Gene Therapy application along with their consumption details: Application 1, Application 2

The time period to estimate the market size:

The history year 2015-2019

The base year 2019

Estimated 2020

Forecast 2020-2023a

Segmentation is concerned with the market share, revenue and growth rate etc. The report shows the high growth period of PharmaSphere: Emerging Biotechnologies-Gene Therapy markets and how can the segments grow during the forecast period.

Ask For Discount@ https://www.regalintelligence.com/check-discount/88714

The main objective of PharmaSphere: Emerging Biotechnologies-Gene Therapy market report is future forecasting, determining opportunities, challenges and threats, making suitable business plans, analyzing market competition and getting advantages and helps in decision making.

This report answers to questions like: Growth rate and market size in 2023a.

Effecting factors, opportunities, challenges, threats of the global PharmaSphere: Emerging Biotechnologies-Gene Therapy market. Competing products.

What M&A activity has taken place in past years.

Table of Contents:

Chapter 1 About the PharmaSphere: Emerging Biotechnologies-Gene Therapy Industry

1.1 Industry Definition and Types

1.2 Main Market Activities

1.3 Similar Industries

1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape

2.1 PharmaSphere: Emerging Biotechnologies-Gene Therapy Markets by Regions

Market Revenue (M USD) and Growth Rate 2015-2023a

Sales and Growth Rate 2015-2023a

Major Players Revenue (M USD) in 2020

2.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Types

2.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Applications

2.4 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

2.4.1 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Revenue and Growth Rate 2015-2020

2.4.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Consumption and Growth rate 2015-2020

2.4.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Price Analysis 2015-2020

Chapter 3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market share

3.1 Major Production Market share by Players

3.2 Major Revenue (M USD) Market share by Players

3.3 Major Production Market share by Regions in 2020, Through 2023a

3.4 Major Revenue (M USD) Market share By Regions in 2020, Through 2023a

Chapter 4 Supply Chain Analysis

4.1 Industry Supply chain Analysis

4.2 Raw material Market Analysis

4.2.1 Raw material Prices Analysis 2015-2020

4.2.2 Raw material Supply Market Analysis

4.2 Manufacturing Equipment Suppliers Analysis

4.3 Production Process Analysis

4.4 Production Cost Structure Benchmarks

4.5 End users Market Analysis

Get Full Report@ https://www.regalintelligence.com/buyNow/88714

Conclusion: This report covers all the necessary information like market landscapes production and consumption analysis, demand and supply analysis, market growth analysis with future predictions and SWOT and PEST analysis, investment and return analysis.

Original post:
PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and...

Recommendation and review posted by Bethany Smith

Logan Howard

Under normal circumstances, graduating seniors gather on Old Campus, clad in zany headwear and surrounded by newly-planted tulips, to partake in the storied traditions that form Class Day. This year, the event was not one day, but seven.The week of reflections and remarks from members of the class of 2020, faculty and alumni culminated with a speech from Jean Bennett 76 on Sunday afternoon.

Seniors received a Class Day care package including tassels, a class anthology and a Yale pin, among other items earlier this week. The Class Day committee, composed of five seniors Sarah Geach 20, Michelle Hu 20, Ananya Indwar 20, Nathan Isaacs 20 and Calvin Schwartzberg 20 encouraged graduates to make masks for their communities rather than the hats that normally characterize the celebration. The past six days have featured remarks from students, faculty members and alumni. On the seventh, Bennett urged graduates to seize the current moment as an opportunity for unity and progress.

We are all now faced with an opportunity for reflection, Bennett said. The world has been so divided, but for once our stress is the same stress something that binds us together.

This terrible experience has created new opportunities and your class will shape things to come. This event will galvanize you all to put your talents, expertise, imagination and passions to good use. You have a huge opportunity to reset to reengineer our world.

Bennett is a professor of ophthalmology at the University of Pennsylvanias Perelman School of Medicine. Her research into retinal diseases led her to develop Luxturna a gene therapy to treat Leber congenital amaurosis, a rare heritable disease that often results in blindness. Luxturna was the first gene therapy ever approved by the Federal Drug Administration for use in humans.

Bennett grew up in New Haven, toured with the Yale Symphony Orchestra in high school and worked in the Universitys biology labs before enrolling as an undergraduate. Reflecting on her time in the Elm City, Bennett recalled anti-Vietnam war movements, the Black Panther trials and a 1:50 ratio of women to men in the sciences.

She drew a connection between researching HIV/AIDS as a Yalie and todays global scientific movement to understand SARS-COV-2.

We do not want to have a future overshadowed by coronavirus, Bennett said. I know that [at] some point we will be able to get back to the projects we put on hold. In the meantime, each of us can try to figure out how to apply our skill the best or to do what we can to contribute.

The Sunday ceremony closed with a performance of Bright College Years by the Yale Bands and Glee Club.

In the days leading up to Bennetts speech, seniors offered their thoughts about the past four years. Joy Qui 20 shared a serious reflection on Tuesday, challenging the idea that all Yale students share fundamental parts of their college experience and the idea that a strong common bond is a positive notion.

The alternative to believing that we share nothing in common would be to believe that Yale is so seductive that four years here is enough to hammer parts of our identities into shapes completely indistinguishable from one another, Qui said.

In a comedic reflection the following day, Simon Fraser 20 and Oscar Lopez 20 congratulated their classmates on something they do all share: the ugliest diploma in America.

We left Yale too early and we had different Yale experiences, Lopez said. Some of us never had the tuna tartar at Harvest.

And some of us still think Shades of Yale is a Facebook group for overhead insults on campus, Fraser responded.

The next several days featured recreations of traditional Old Campus activities such as Vincent Vaughnss 20 Ivy Ode, An Ode to Fight, delivered with an ivy plant in the frame. The class of 2020 will plant their sprig of ivy on Old Campus when it is safe to return. Dean Marvin Chun saluted graduating seniors on their accomplishments, seniors submitted photos and memories from the past four years for a class slideshow and scores of alumni offered a toast to the class of 2020 in video form.

The University is planning to host an in-person celebration of the graduates at a later date.

Mackenzie Hawkins |mackenzie.hawkins@yale.edu

Read the original post:
Virtual Class Week concludes with Bennett's message: You have a huge opportunity to reset - Yale Daily News

Recommendation and review posted by Bethany Smith

Doctors in Southern California are working with researchers in Arizona to better understand the bodys sometimes bizarre immune response to COVID-19 an antibody onslaught that may kill the patient, rather than kill the virus.

The nonprofit Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is peering into specific proteins on the virus to see how they react with different antibodies a high-resolution view that might guide treatment, testing and vaccine development.

The hypothesis is that antibodies can make things worse, and thats whats killing some people, said John Altin, assistant professor in TGens infectious-disease branch. We want to understand how that might be different from an immune response that protects somebody.

As many critically ill patients are treated in clinical trials with convalescent plasma therapy that is, injecting antibodies from recovered COVID-19 patients into those who are very ill, in hopes of triggering protective immune responses its imperative to understand whats behind the differing reactions.

Usually, antibodies provide protection, but there may be a bit of an exception with this virus, Altin said. That is a serious concern.

To that end, TGen and the Center for Gene Therapy at City of Hope are cooperating on a COVID Immunity Study that aims to collect blood from COVID-19 survivors.

The researchers will analyze your blood and profile your immune memory, the study consent form explains.

Participants can use the TGen kit at home. Theyll get a study kit by mail and collect one small spot blood sample, via a finger-prick device, for two consecutive weeks. Then theyll mail the study kit back to TGen.

About 500 people are expected to participate through the course of the study, and researchers may reach out for additional samples, and/or with additional questions, to see how immune memory changes over time.

Participants must be U.S. residents, at least 18 years old, have tested positive for COVID-19, and then recovered. For more information, see https://covidimmunity.org/.

This will help us learn more about how, when and why we produce antibodies in response to a COVID-19 infection, said David Engelthaler, director of TGen North, in a prepared statement. One class of antibodies tackles the infection first, and then another comes in to finish the job. Knowing when these different immune responses occur, and how long they last, could help us understand if some patients gain a certain degree of immunity against reinfection. We need to know how that works.

While large-scale clinical trials involving convalescent plasma are under way all over the nation, this study aims not to treat the disease, but to better understand the mechanisms behind it.

TGen describes its approach as a high-resolution view of the antibody response. It seeks to not only map the viruss proteins in detail, but to also see which parts of those proteins are targeted by antibodies.

Our approach will not only tell you which proteins arebeing targeted, but also be able to tell which regions of each protein are being targeted, Altin said in a statement. Each protein can be recognized by many different types of antibodies. By looking at this level of detail, we then could see elements of the antibody response that others might be missing.

TGen hopes to tease out subtle differences that can help develop therapies, vaccines and better antibody testing.

Others are looking at responses to the entire protein. Our approach is a little different. When we look at the antibody response, we divide it up into thousands of pieces. Theres potential for that to tell us what a beneficial and un-beneficial response might look like, Altin said.

John Zaia, director of the Center for Gene Therapy at City of Hope, is working with TGen, and has other COVID-19-related projects happening as well.

Zaia is leading a research project at City of Hope, in collaboration with Altins lab, that could lead to development of a COVID-19 virus antibody neutralization test, which would quantify antibodies.

Zaia also has received a $750,000 grant from the California Institute for Regenerative Medicine for a clinical study on the use of blood plasma as a potential treatment for COVID-19.

Theyre doing what you could call qualitative and quantitative measurements of the nature of the antibody what does it actually bind to? Zaia said. The virus has this surface protein, the spike protein, but there are also other things the immune system might be seeing. It might be focused on one or more parts of the spike.

The CIRM project will focus on finding plasma donors to determine if theres any correlation between the outcome in the sick patient who received the plasma and the specific antibody that went in. It will focus on under-served areas.

Duarte-based City of Hope was founded in 1913 and is a founding member of the National Comprehensive Cancer Network. It has many sites throughout Southern California, and is investing $1 billion to establish clinics and a cancer center in Orange County. A clinic opened in Newport Beach in January, and a hospital dedicated to cancer treatment and research is slated for Irvine.

On the forefront of science, new discoveries are made every day and so much is still unknown.

I think the FDA said it best: Theres no way that one group could solve all the problems, do all the testing that needs to be done, Zaia said. The whole field is so new.

Theres a balance that must be struck between moving quickly and moving carefully, Altin said. We should know a lot in the next three months about how the antibody response looks, he said. Vaccine development will take much longer.

The rest is here:
Why does immune response to coronavirus save some, kill others? - OCRegister

Recommendation and review posted by Bethany Smith

In wide-ranging congressional testimony, the ousted head of an agency at the center of the federal governments Covid-19 vaccine and treatment response criticized the Trump administration for a slow-footed federal response that could resound throughout the course of the pandemic.

I believe we could have done better, Rick Bright, former chief of the Biomedical Advanced Research and Development Authority (BARDA), told a House subcommittee. We dont have the right leadership for this response and we dont have the right plan for this response.

Bright, who has headed BARDA since 2016, was removed from his post in April. Several days later, he accused HHS of reassigning him because he opposed efforts to put significant funds behind Covid-19 drugs not supported by data, including the anti-malarial hydroxychloroquine. Bright subsequently filed a whistleblower complaint detailing a long history of political interference at the agency, setting up a much-anticipated congressional hearing on Thursday.

Thursday morning, in the leadup to Brights testimony, President Trump dismissed Bright on Twitter as a disgruntled employee who he had never heard of. And HHS released a lengthy rebuttal to the whistleblower complaints, setting the stage for some of the line of questioning Republicans used during the hearing.

Mr. Bright has not yet shownup for work, but continues to collect his $285,010 salary, while using his taxpayer-funded medical leave to work with partisan attorneys who are politicizing the response to COVID-19, a spokesperson said in an emailed statement. His whistleblower complaint is filled with one-sided arguments and misinformation.

The Office of Special Counsel, a government watchdog, however, preliminarily determinedtoday there was evidence backing Brights claims and that he should be reinstated.

Unstrapping a black cloth mask to testify, Bright pointed to mismanagement at HHS from the early days of the pandemic. He said he tried to secure a sample of the virus in January to help expedite the development of vaccines, treatments and diagnostics, but the agency was not able to acquire one until February. He attempted to get funding for vaccines and countermeasures in his first meeting with HHS secretary Alex Azar, he said, but Azar was puzzled by his question, he said, and over the months his continued calls for urgency led to him being shut out.

I was told that my urgings caused a commotion and I was removed from those meetings, Bright said.

He pointed to emails, mentioned from his whistleblower complaint, he received in January from Mike Bowen, the head of mask manufacturer Prestige Ameritech, offering N95s and warning the US had insufficient domestic supply.

He said were in deep shit, the world is, and we need to act and I pushed that forward to the highest levels I could in HHS and got no response, Bright said. From that point I knew we were going to have a crisis.

In their statement, HHS said Bright was not responsible for masks and said Brights assumption that others were not concerned with and working on various workstreams related to COVID-19 preparedness is bizarre and false.

Although Brights complaint pinned his ouster on his opposition to hydroxychloroquine, journalists pointed out that Brights signature was on the documents authorizing the emergency use of the pill for Covid-19 patients. In their statement, HHS called Bright the sponsor of the hydroxychloroquine effort who celebrated when the government was able to secure the supply.

Bright told the House that he had been directed to file those authorizations by the Trump administration. He argued the supply was necessary for clinical trials but not outside it. Alongside other government scientists, he said, he had worked to push back on administration efforts to set up an expanded access protocol by which people including those who hadnt tested positive to Covid-19 could have access to the potentially dangerous drug outside of a hospital. We had to come up with an alternate solution that the administration would accept, he said.

While initially successful, Bright said, he then learned of and spoke out against a subsequent government plan to flood New York and New Jersey with the anti-malarial, leading to his ouster.

That was the straw that broke the camels back, Bright recalled, and expedited my removal.

Turning toward more recent controversy, Bright said a chaotic government response has endangered patients and could impede the response going forward. Over the week-and-a-half since the FDA authorized the use of remdesivir as the first drug shown to have efficacy against Covid-19, doctors have sharply criticized the government for how theyve distributed the Gilead antiviral, with no clear criteria announced and some hospitals with larger numbers of patients unable to secure a supply.

Bright was no longer at BARDA when remdesivir was authorized, but he said no plan had been put in place to prepare for when it was.

There was never action taken on the urgency to come up with a plan for acquisition of limited doses, Bright said, nor to distribute the limited doses of remdesivir.

Now, Bright said, similar problems loom for potential vaccines, once theyre shown to work. Although BARDA and the leading vaccine companies have put significant funds into scaling up manufacturing, an approved vaccine will still come in batches rather than all at once, posing a need to equitably distribute the doses until they are available. Bright revealed that the government had secured access to some of those doses with their funding agreements, but he said theres little plan for how to give them out.

Its going to be a limited supply, Bright said. We need to have a strategy and a plan in place now. We dont have that yet and it is a significant concern.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

Read more:
Rick Bright details mismanaged pandemic response, warns of drugs, vaccine supply problems down the road; HHS pushes back - Endpoints News

Recommendation and review posted by Bethany Smith